[{"address1": "1500 Broadway", "address2": "Suite 1401", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "332 208 6102", "website": "https://www.nuvationbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.", "fullTimeEmployees": 159, "companyOfficers": [{"maxAge": 1, "name": "Dr. David T. Hung M.D.", "age": 65, "title": "Founder, President, CEO & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1000605, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Hattersley Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 694558, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Liu M.D., Ph.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 677151, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Moses  Makunje CPA", "age": 44, "title": "VP of Finance and Principal Accounting & Financial Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stacy  Markel", "age": 58, "title": "Chief People Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David C. Hanley Ph.D.", "age": 53, "title": "Chief Technical Operations Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 586040, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kerry A. Wentworth", "age": 50, "title": "Chief Regulatory Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Colleen  Sjogren", "age": 53, "title": "Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Junyuan  Wang Ph.D.", "age": 50, "title": "CEO & Co-Founder of AnHeart Therapeutics and Director", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.28, "open": 3.25, "dayLow": 3.22, "dayHigh": 3.75, "regularMarketPreviousClose": 3.28, "regularMarketOpen": 3.25, "regularMarketDayLow": 3.22, "regularMarketDayHigh": 3.75, "beta": 1.4, "forwardPE": -8.395349, "volume": 2083920, "regularMarketVolume": 2083920, "averageVolume": 1646922, "averageVolume10days": 1601250, "averageDailyVolume10Day": 1601250, "bidSize": 2900, "askSize": 4000, "marketCap": 895897344, "fiftyTwoWeekLow": 0.95, "fiftyTwoWeekHigh": 4.16, "fiftyDayAverage": 3.1058, "twoHundredDayAverage": 2.20172, "currency": "USD", "enterpriseValue": 298842048, "floatShares": 148181275, "sharesOutstanding": 247171008, "sharesShort": 14275676, "sharesShortPriorMonth": 11609351, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0575, "heldPercentInsiders": 0.2721, "heldPercentInstitutions": 0.5286, "shortRatio": 6.6, "shortPercentOfFloat": 0.0933, "impliedSharesOutstanding": 248171008, "bookValue": 2.711, "priceToBook": 1.3316119, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -68868000, "trailingEps": -0.32, "forwardEps": -0.43, "enterpriseToEbitda": -3.204, "52WeekChange": 1.1878788, "SandP52WeekChange": 0.19608545, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "NUVB", "underlyingSymbol": "NUVB", "shortName": "Nuvation Bio Inc.", "longName": "Nuvation Bio Inc.", "firstTradeDateEpochUtc": 1598448600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "292fc361-56ab-3994-b08a-1a4c45c2f81b", "messageBoardId": "finmb_639036735", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.61, "targetHighPrice": 10.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.6, "targetMedianPrice": 5.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 596976000, "totalCashPerShare": 2.415, "ebitda": -93276000, "totalDebt": 3532000, "quickRatio": 38.146, "currentRatio": 38.577, "debtToEquity": 0.595, "returnOnAssets": -0.09201, "returnOnEquity": -0.11152001, "freeCashflow": -41272500, "operatingCashflow": -64371000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-25"}]